168 related articles for article (PubMed ID: 30835576)
1. Review of Published Bitter Orange Extract and
Stohs SJ; Ray SD
J Diet Suppl; 2020; 17(3):355-363. PubMed ID: 30835576
[No Abstract] [Full Text] [Related]
2. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p-synephrine.
Stohs SJ; Preuss HG; Shara M
Phytother Res; 2011 Oct; 25(10):1421-8. PubMed ID: 21480414
[TBL] [Abstract][Full Text] [Related]
3. Safety, Efficacy, and Mechanistic Studies Regarding Citrus aurantium (Bitter Orange) Extract and p-Synephrine.
Stohs SJ
Phytother Res; 2017 Oct; 31(10):1463-1474. PubMed ID: 28752649
[TBL] [Abstract][Full Text] [Related]
4. [Synephrine in dietary supplements and specialized foodstuffs: biological activity, safety and methods of analysis].
Perova IB; Eller KI; Musatov AV; Tymolskaya EV
Vopr Pitan; 2021; 90(6):101-113. PubMed ID: 35032130
[TBL] [Abstract][Full Text] [Related]
5. A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract.
Kaats GR; Miller H; Preuss HG; Stohs SJ
Food Chem Toxicol; 2013 May; 55():358-62. PubMed ID: 23354394
[TBL] [Abstract][Full Text] [Related]
6. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine.
Stohs SJ; Preuss HG; Shara M
Int J Med Sci; 2012; 9(7):527-38. PubMed ID: 22991491
[TBL] [Abstract][Full Text] [Related]
7. Effect of acute administration of an herbal preparation on blood pressure and heart rate in humans.
Seifert JG; Nelson A; Devonish J; Burke ER; Stohs SJ
Int J Med Sci; 2011 Mar; 8(3):192-7. PubMed ID: 21448304
[TBL] [Abstract][Full Text] [Related]
8. HPLC-UV-QDa analysis of Citrus aurantium-labelled pre-workout supplements suggest only a minority contain the plant extract.
Koh AHW; Chess-Williams R; Lohning AE
J Pharm Biomed Anal; 2021 Jan; 193():113746. PubMed ID: 33190081
[TBL] [Abstract][Full Text] [Related]
9. Physiological effects following administration of Citrus aurantium for 28 days in rats.
Hansen DK; George NI; White GE; Pellicore LS; Abdel-Rahman A; Fabricant D;
Toxicol Appl Pharmacol; 2012 Jun; 261(3):236-47. PubMed ID: 22521485
[TBL] [Abstract][Full Text] [Related]
10. [Risk assessment of synephrine in dietary supplements].
Bakhyia N; Dusemund B; Richter K; Lindtner O; Hirsch-Ernst KI; Schäfer B; Lampen A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2017 Mar; 60(3):323-331. PubMed ID: 28058460
[TBL] [Abstract][Full Text] [Related]
11. Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS.
Pawar RS; Sagi S; Leontyev D
Drug Test Anal; 2020 Sep; 12(9):1241-1251. PubMed ID: 32497396
[TBL] [Abstract][Full Text] [Related]
12. Effects of Citrus aurantium (bitter orange) fruit extracts and p-synephrine on metabolic fluxes in the rat liver.
Peixoto JS; Comar JF; Moreira CT; Soares AA; de Oliveira AL; Bracht A; Peralta RM
Molecules; 2012 May; 17(5):5854-69. PubMed ID: 22592089
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety of Oral p-Synephrine (Bitter Orange) in Healthy Subjects: A Randomized Placebo-Controlled Cross-over Clinical Trial.
Shara M; Stohs SJ; Mukattash TL
Phytother Res; 2016 May; 30(5):842-7. PubMed ID: 26948284
[TBL] [Abstract][Full Text] [Related]
14. Response of CEDIA amphetamines assay after a single dose of bitter orange.
Nguyen DT; Bui LT; Ambrose PJ
Ther Drug Monit; 2006 Apr; 28(2):252-4. PubMed ID: 16628139
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometric determination of the predominant adrenergic protoalkaloids in bitter orange (Citrus aurantium).
Nelson BC; Putzbach K; Sharpless KE; Sander LC
J Agric Food Chem; 2007 Nov; 55(24):9769-75. PubMed ID: 17966980
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of p-synephrine following 15 days of oral administration to healthy subjects: A clinical study.
Shara M; Stohs SJ; Smadi MM
Phytother Res; 2018 Jan; 32(1):125-131. PubMed ID: 29130542
[TBL] [Abstract][Full Text] [Related]
17. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain?
Allison DB; Cutter G; Poehlman ET; Moore DR; Barnes S
Int J Obes (Lond); 2005 Apr; 29(4):443-6. PubMed ID: 15700046
[TBL] [Abstract][Full Text] [Related]
18. Bitter orange (
Deshmukh NS; Stohs SJ; Magar CC; Kale A; Sowmya B
Toxicol Rep; 2017; 4():598-613. PubMed ID: 29214145
[TBL] [Abstract][Full Text] [Related]
19. A review of the receptor-binding properties of p-synephrine as related to its pharmacological effects.
Stohs SJ; Preuss HG; Shara M
Oxid Med Cell Longev; 2011; 2011():482973. PubMed ID: 21904645
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
